In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
about
Pentavalent antimonials: new perspectives for old drugsLow versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil.Clinical and experimental advances in treatment of visceral leishmaniasis.Factors associated to adherence to different treatment schemes with meglumine antimoniate in a clinical trial for cutaneous leishmaniasis.Monitoring drug resistance in leishmaniasis.Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages.In vitro and in vivo activities of a triterpenoid saponin extract (PX-6518) from the plant Maesa balansae against visceral leishmania species.A novel marker, ARM58, confers antimony resistance to Leishmania sppUse of antimony in the treatment of leishmaniasis: current status and future directions.Antimony resistance in leishmania, focusing on experimental research.Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasitesIFN-γ-induced macrophage antileishmanial mechanisms in mice: A role for immunity-related GTPases, Irgm1 and Irgm3, in Leishmania donovani infection in the liver.Aquaglyceroporins and metalloid transport: implications in human diseases.Pharmacokinetics of experimental pentavalent antimony after intramuscular administration in adult volunteers.Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c miceAntimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.Gene expression analysis of the mechanism of natural Sb(V) resistance in Leishmania donovani isolates from Nepal.Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes.Glutathione-induced conversion of pentavalent antimony to trivalent antimony in meglumine antimoniate.Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes.Reduction of Sb(V) in a human macrophage cell line measured by HPLC-ICP-MS.Gene amplification in Leishmania tarentolae selected for resistance to sodium stibogluconate.Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action.An axenic amastigote system for drug screeningAxenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.Pentostam induces resistance to antimony and the preservative chlorocresol in Leishmania donovani promastigotes and axenically grown amastigotes.Antileishmanial drugs cause up-regulation of interferon-gamma receptor 1, not only in the monocytes of visceral leishmaniasis cases but also in cultured THP1 cells.Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening.Antimony-induced cardiomyopathy in guinea-pig and protection by L-carnitine.Treatment of cutaneous leishmaniasis with a combination of allopurinol and low-dose meglumine antimoniate.Retrospective study of 151 patients with cutaneous leishmaniasis treated with meglumine antimoniate.Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.
P2860
Q28253055-20E13BD0-9E81-48BE-95BA-17579790A4B5Q33739398-345D47FB-78B9-46D7-AD60-A265FCEA6B8CQ33982648-5FB81F76-D71B-4950-98FF-C1100526FFA1Q34040777-AF2DC695-F935-490C-827B-996CBDB84801Q34434828-745E79CB-0142-42ED-B359-1B118FE342C4Q34648790-D03034E2-093F-4433-8047-EAC618D82E71Q35006918-5A9C82EC-58C5-48B9-8234-EBE9F0EC5251Q35111617-850F8B33-E7FC-476D-BE24-D2F2716731E1Q35377767-7618A92A-F931-4176-8AA6-2418720D722FQ35607561-CCC05CE3-42A8-46CB-A2C4-DC16124F94CFQ36047995-DD57EE47-BDE5-47E5-8A35-1921C2889ECDQ36267823-6A98D420-E672-4DA9-BEDA-74E9D9CAE90FQ37310939-15AAD2C8-7A51-42EF-A3F2-10DFB033CABFQ37663500-E55DF7D9-D87A-4795-A3D7-1AACFE205243Q37674869-D70B019B-E866-4895-A18E-39571BC4E951Q38914848-79C579AA-58A5-4FF9-A6AD-0D3184C5F940Q38968281-7A5B30C1-0A20-4A25-8925-90EF249EA083Q39469739-DDD79626-1990-474E-AD9E-F2DDCC15134CQ39476650-0D3EDBBF-B4D5-4D1F-A151-56F95BB58395Q39477783-1727E312-7AB0-49D2-A7A6-44936E169960Q39535308-2FB5295E-99EC-4BA1-8173-0BC59D65EC54Q39557983-903EC8A0-D80E-4E6E-8582-C0EA91FC3C0BQ39559595-BC777943-163B-4CC9-B46A-5C3C03BD8943Q39783960-860C0228-D698-4C23-83AC-0445967EC88EQ39784088-FFD390A3-80C1-42C1-88E3-6F7F5FD420C5Q39784148-28A939AA-F49D-4275-93A8-280F160C2DEEQ40640236-EEB7E8D5-7A01-4B51-9B36-BD92DB4A602DQ41387479-651CB87E-AC14-4CD9-B780-ED8CFE4A08C8Q41844113-7A81C5A0-DC11-4702-BBA6-456DAEB07465Q42806745-1EE8274E-FA6E-4333-8D24-D90391707B54Q42948051-78A185B6-FD47-4E27-913E-5B4B5CFD4ADFQ43261588-49838368-AB62-4456-9D71-F949A39809CEQ44066578-D30B2D00-590A-4EFE-8ABF-4971ACFC13B9Q46491606-90E51451-AD5E-4C45-ACDE-CCBD3B1D8D1DQ54027189-E2957D90-C53F-4CA2-92DD-E03A7C4ACAAB
P2860
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@en
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@nl
type
label
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@en
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@nl
prefLabel
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@en
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@nl
P2093
P2860
P356
P1476
In vitro antileishmanial properties of tri- and pentavalent antimonial preparations.
@en
P2093
P2860
P304
P356
10.1128/AAC.39.6.1234
P407
P577
1995-06-01T00:00:00Z